Patients are significantly more likely to experience treatment-related cardiac events with osimertinib than with other EGFR TKIs, data suggest.

A two-drug combination extended OS compared with standard first-line osimertinib for certain patients with advanced lung ...

The Head and Neck Radiation Oncology Group (GORTEC) announced significant improvement in disease-free survival for locally ...

FDA grants priority review tag to JNJ's nipocalimab BLA for gMG and asks for new warnings on GSK & PFE's RSV vaccine labels.

In this edition of InnovationRx, medical debts will be erased from credit histories, this farm is doubling down on raw milk ...

Dame Esther responded after a columnist tried to use her own cancer experience as an argument against assisted dying.

Johnson & Johnson (J&J) has reported positive topline outcomes from the Phase III MARIPOSA trial of Rybrevant ...

As a wave of volatility has been re-introduced to the system, investors are flocking toward blue-chip companies for stability ...

Cullinan Therapeutics’ strong financial position funds growth into 2028. Find out why CGEM stock presents a compelling buy ...

Reaching more mUM patients globally with KIMMTRAK (tebentafusp) in 2025 through additional launches and increased community penetrationEnrolling ...

Johnson & Johnson released results from a phase 3 study, showing that the combination of Rybrevant and Lazcluze significantly improved overall survival in patients with advanced non-small cell lung ...

Johnson & Johnson announced positive topline results for the gold standard endpoint in cancer treatment of overall survival, or OS, from ...